Renexxion and Dr. Falk Pharma Begin U.S. Patient Dosing in Global Phase 2b Study for Promising Gastroparesis Treatment

Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high u...

August 14, 2024 | Wednesday | News
Parexel’s Greenhouse Gas Reduction Targets Earn SBTi Validation, Marking Key Milestone in Net-Zero Commitment

Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services,...

August 13, 2024 | Tuesday | News
Shanghai Junshi Biosciences’ Toripalimab sNDA Accepted by NMPA for First-Line Treatment of Advanced Melanoma

Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of ...

August 13, 2024 | Tuesday | News
Stereotaxis Announces CE Mark Approval and FDA Submission for Revolutionary GenesisX Robotic System

Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE mark in Eu...

August 13, 2024 | Tuesday | News
Angiex Initiates Phase 1 Trial of Innovative AGX101 Cancer Therapy with Abzena's Support

Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for...

August 09, 2024 | Friday | News
Angiex Initiates Phase 1 Clinical Trial for AGX101, a First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for Solid Tumors

Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for...

August 09, 2024 | Friday | News
MSD Discontinues Phase 3 KeyVibe-008 Trial for Extensive-Stage Small Cell Lung Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada,  announced the discontinuation of the Phase 3 KeyVibe-008 trial based on th...

August 09, 2024 | Friday | News
NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines

    NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria...

August 08, 2024 | Thursday | News
Novartis' Fabhalta® Receives FDA Accelerated Approval for IgA Nephropathy Treatment

Novartis is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta® (iptacopan), a ground...

August 08, 2024 | Thursday | News
Kiromic BioPharma Announces Promising Eight-Month Results from Deltacel-01 Phase 1 Trial

Kiromic BioPharma, reports favorable eight-month follow-up results from the first patient enrolled in its Deltacel-01 Phase 1 clinical trial. This trial ...

August 02, 2024 | Friday | News
MSD Announces Positive CHMP Opinion for KEYTRUDA® and Padcev® Combo in Advanced Urothelial Carcinoma

MSD (NYSE: MRK), known as Merck & Co., Inc. in the United States and Canada, today announced that the European Medicines Agency’s Committee for...

July 29, 2024 | Monday | News
Eisai Adopts Medidata’s AI-Driven Clinical Data Studio for Enhanced Clinical Trial Management

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. (&l...

July 29, 2024 | Monday | News
Lusvertikimab Shows Significant Efficacy in Phase 2 CoTikiS Study for Ulcerative Colitis

    Lusvertikimab demonstrates significant efficacy during the 10 week-induction phase of treatment, in the randomized double-blind CotiKis p...

July 24, 2024 | Wednesday | News
Pfizer Announces Positive Results from Phase 3 Study of Investigational Gene Therapy for Hemophilia A

Pfizer Inc. announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gen...

July 24, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close